LncRNA ZNRD1-AS1 Promotes Malignant Lung Cell Proliferation, Migration, and Angiogenesis Via the MiR-942/TNS1 Axis and is Positively Regulated by the MA Reader YTHDC2
Overview
Oncology
Affiliations
Rationale: Lung cancer is the most prevalent form of cancer and has a high mortality rate, making it a global public health concern. The N-methyladenosine (mA) modification is a highly dynamic and reversible process that is involved in a variety of essential biological processes. Using in vitro, in vivo, and multi-omics bioinformatics, the present study aims to determine the function and regulatory mechanisms of the long non-coding (lnc)RNA zinc ribbon domain-containing 1-antisense 1 (ZNRD1-AS1).
Methods: The RNAs that were bound to the mA 'reader' were identified using YTH domain-containing 2 (YTHDC2) RNA immunoprecipitation (RIP)-sequencing. Utilizing methylated RIP PCR/quantitative PCR, pull-down, and RNA stability assays, mA modification and ZNRD1-AS1 regulation were analyzed. Using bioinformatics, the expression levels and clinical significance of ZNRD1-AS1 in lung cancer were evaluated. Using fluorescent in situ hybridization and quantitative PCR assays, the subcellular location of ZNRD1-AS1 was determined. Using cell migration, proliferation, and angiogenesis assays, the biological function of ZNRD1-AS1 in lung cancer was determined. In addition, the tumor suppressor effect of ZNRD1-AS1 in vivo was validated using a xenograft animal model. Through bioinformatics analysis and in vitro assays, the downstream microRNAs (miRs) and competing endogenous RNAs were also predicted and validated.
Results: This study provided evidence that mA modification mediates YTHDC2-mediated downregulation of ZNRD1-AS1 in lung cancer and cigarette smoke-exposed cells. Low levels of ZNRD1-AS1 expression were linked to adverse clinicopathological characteristics, immune infiltration, and prognosis. ZNRD1-AS1 overexpression was shown to suppress lung cancer cell proliferation, migration, and angiogenesis in vitro and in vivo, and to reduce tumor growth in nude mice. ZNRD1-AS1 expression was shown to be controlled by treatment of cells with either the methylation inhibitor 3-Deazaadenosine or the demethylation inhibitor Meclofenamic. Furthermore, the miR-942/tensin 1 (TNS1) axis was demonstrated to be the downstream regulatory signaling pathway of ZNRD1-AS1.
Conclusions: ZNRD1-AS1 serves an important function and has clinical relevance in lung cancer. In addition, the findings suggested that mA modification could mediate the regulation of the ZNRD1-AS1/miR-942/TNS1 axis via the mA reader YTHDC2.
Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y EXCLI J. 2025; 24:113-150.
PMID: 39967906 PMC: 11830918. DOI: 10.17179/excli2024-7935.
Tian F, He X, Wang S, Liang Y, Wang Z, Hu M Apoptosis. 2025; .
PMID: 39948301 DOI: 10.1007/s10495-024-02061-1.
The therapeutic potential of RNA m(6)A in lung cancer.
Yu J, Sun W, Zhao X, Chen Y Cell Commun Signal. 2024; 22(1):617.
PMID: 39736743 PMC: 11687105. DOI: 10.1186/s12964-024-01980-5.
The role of N6-methyladenosine modification in tumor angiogenesis.
Qin L, Zeng X, Qiu X, Chen X, Liu S Front Oncol. 2024; 14:1467850.
PMID: 39691597 PMC: 11649548. DOI: 10.3389/fonc.2024.1467850.
Zhao Y, Han S, Zeng Z, Zheng H, Li Y, Wang F Theranostics. 2024; 14(18):7088-7110.
PMID: 39629121 PMC: 11610135. DOI: 10.7150/thno.99197.